NorthShore University HealthSystem offers expanded access to treat most common prostate ailment
16 Agosto 2023 - 2:00PM
NorthShore University HealthSystem (NorthShore) and PROCEPT
BioRobotics® announce a significant milestone in access to
treatment of Benign Prostatic Hyperplasia (BPH). NorthShore’s
Highland Park Hospital has become the first hospital in the United
States to install a second AquaBeam Robotic System that delivers
the cutting-edge Aquablation® therapy procedure, which removes
prostate tissue while minimizing side effects such as ejaculatory
function and preserving erectile function and continence.
NorthShore will also install a third AquaBeam system at Swedish
Hospital on the north side of Chicago.
BPH is the most common prostate ailment, affecting
nearly 40 million men in the United States, with more than half of
men aged 50 and above impacted by the condition. Symptoms include
frequent or urgent urination, weak urine flow and incomplete
emptying of the bladder, often causing significant discomfort and
negatively impacting quality of life. Aquablation has been in
increasing demand for treatment of lower urinary tract symptoms
(LUTS) resulting from BPH.
"Aquablation therapy has revolutionized the way we
treat BPH. Its exceptional clinical outcomes, including significant
improvements in urinary symptoms and preservation of sexual
function, along with low complication rates have led me to
transition nearly all my BPH cases to this transformative
technology," said Dr. Brian Helfand, NorthShore’s Chief of Urology
and Clinical Professor at the University of Chicago. “We have
become a national and international destination for this surgery
and have treated men from all over the U.S. and six countries.”
Since 2019, Dr. Helfand and the NorthShore team of
urologic specialists have used Aquablation to treat more than 700
patients at Highland Park Hospital, one of the first locations in
the U.S. with an Aquablation program to train urologists from
across the country to learn how to use Aquablation technology.
Aquablation therapy is the first and only
image-guided, automated, heat-free robotic therapy for the
treatment of BPH. The system’s real-time ultrasound imaging
provides the surgeon with a multi-dimensional view of the prostate
enabling personalized treatment planning tailored to each patient’s
unique anatomy. The surgeon can specify which areas of the prostate
to remove to minimize side effects, such as erectile dysfunction
and incontinence. Once the treatment plan is mapped, the automated
robot removes prostate tissue in a precise, targeted and controlled
fashion using novel, heat-free waterjet technology.
The tremendous growth in Aquablation procedures is
supported by a wealth of clinical evidence, including two
significant FDA trials – WATER and WATER II. These trials, with
five-year follow-up, show Aquablation therapy’s consistent results
across various prostate anatomies, demonstrating long-term symptom
relief while preserving sexual function and continence for
patients.
Sham Shiblaq, PROCEPT BioRobotics’ EVP and Chief
Commercial Officer, remarked, "NorthShore’s installation of two
additional AquaBeam systems highlights the ongoing shift in the
standard of care for BPH treatment. Aquablation is poised to
replace traditional procedures like TURP (transurethral resection
of the prostate) nationwide, thanks to its consistent and
long-lasting outcomes and superior safety profile, regardless of
prostate size, shape or surgeon experience."
For more information about NorthShore University
HealthSystem’s urological services and to schedule an appointment,
visit www.northshore.org/urological-health. To learn more about
Aquablation therapy, visit Aquablation.com.
About NorthShore – Edward-Elmhurst
Health NorthShore – Edward-Elmhurst Health is a fully
integrated healthcare delivery system committed to providing access
to quality, vibrant, community-connected care, serving an area of
more than 4.2 million residents across six northeast Illinois
counties. Our more than 27,000 team members and more than 7,000
physicians aim to deliver transformative patient experiences and
expert care close to home across more than 300 ambulatory locations
and eight acute care hospitals – Edward (Naperville), Elmhurst,
Evanston, Glenbrook (Glenview), Highland Park, Northwest Community
(Arlington Heights), Skokie and Swedish (Chicago) – all recognized
as Magnet hospitals for nursing excellence. Located in Naperville,
Linden Oaks Behavioral Health, provides for the mental health needs
of area residents. For more information, visit
NorthShore.org, SwedishCovenant.org, NCH.org and
EEHealth.org.
About PROCEPT BioRobotics
Corporation PROCEPT BioRobotics is a surgical robotics
company focused on advancing patient care by developing
transformative solutions in urology. PROCEPT BioRobotics develops,
manufactures and sells the AquaBeam Robotic System, an advanced,
image-guided, surgical robotic system for use in minimally invasive
urologic surgery with an initial focus on treating benign prostatic
hyperplasia, or BPH. BPH is the most common prostate disease and
impacts approximately 40 million men in the United States. PROCEPT
BioRobotics designed Aquablation therapy to deliver effective, safe
and durable outcomes for males suffering from lower urinary tract
symptoms, or LUTS, due to BPH that are independent of prostate size
and shape or surgeon experience. PROCEPT BioRobotics has developed
a significant and growing body of clinical evidence, which includes
nine clinical studies and over 150 peer-reviewed publications,
supporting the benefits and clinical advantages of Aquablation
therapy. Important Safety Information
All surgical treatments have inherent and
associated side effects. For a list of potential side effects,
visit https://aquablation.com/safety-information/.
Media Contact: Matt Bacso, CFA
VP, Investor Relations and Business Operations
m.bacso@procept-biorobotics.com
Contact: Keith HartenbergerPhone:
630-527-3929keith.hartenberger@eehealth.org
Grafico Azioni PROCEPT BioRobotics (NASDAQ:PRCT)
Storico
Da Ago 2024 a Set 2024
Grafico Azioni PROCEPT BioRobotics (NASDAQ:PRCT)
Storico
Da Set 2023 a Set 2024